Literature DB >> 31192764

Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth.

Yuanyuan Sun1, Suya Wang1, Hainan Yang1, Jiangping Wu1, Sha Li1, Guoliang Qiao1, Shuo Wang1, Xiaoli Wang1, Xinna Zhou1, Takuya Osada2, Amy Hobeika2, Michael A Morse3,2, Jun Ren1,2, Herbert Kim Lyerly2.   

Abstract

Aim: The purpose of this study was to determine whether addition of anti-PD-1 antibody increased the immunogenicity and anti-tumor activity of Ad-CEA vaccination in a murine model of colon cancer.
Methods: Ad-CEA was administered prior to implantation of MC-38-CEA cells followed by administration of anti-PD-1 antibody. CEA-specific T-cell responses were measured by flow cytometry and ELISPOT. Dynamic co-culture of splenocytes with tumor cells was conducted to analyze anti-tumor activities. Tumor infiltration by lymphocytes was measured by IHC. Tumor volume and overall survival were also recorded.
Results: Ad-CEA combined with anti-PD-1 antibody showed greater anti-tumor activity compared with either alone. The combination also increased T-cell infiltration but decreased Tregs.
Conclusion: Combining Ad-CEA vaccination with anti-PD-1 antibody enhanced anti-tumor activity and immune responses.

Entities:  

Keywords:  CEA; PD-1 blockade; colon cancer; immunotherapy; microenvironment; tumor vaccine

Mesh:

Substances:

Year:  2019        PMID: 31192764     DOI: 10.2217/imt-2019-0055

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  3 in total

Review 1.  Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.

Authors:  Chongxian Pan; Hongtao Liu; Elizabeth Robins; Wenru Song; Delong Liu; Zihai Li; Lei Zheng
Journal:  J Hematol Oncol       Date:  2020-04-03       Impact factor: 17.388

Review 2.  Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2020-11-18       Impact factor: 5.048

3.  Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio.

Authors:  Erika J Crosby; Amy C Hobeika; Donna Niedzwiecki; Christel Rushing; David Hsu; Peter Berglund; Jonathan Smith; Takuya Osada; William R Gwin Iii; Zachary C Hartman; Michael A Morse; Herbert Kim Lyerly
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.